Gilead Sciences, Inc. (0QYQ)
LSE
147.50
+4.00 (+2.79%)
Closed
Oct 7, 2026
Day's Range
143.00148.71
52 wk Range
112.62157.79
Financial Statements - 0QYQ - Gilead Sciences, Inc.
Revenue
29.44B▲ 2.4%
Net Income
8.51B▲ 1672.9%Net Margin 28.9%
EBITDA
14.80B▲ 9.3%
Free Cash Flow
9.45B▼ 8.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 29.44B | 28.75B | 27.11B | 27.28B | 27.30B | 24.68B |
| Cost of Goods | 6.23B | 6.25B | 6.49B | 5.65B | 6.60B | 4.57B |
| Gross Profit | 23.20B | 22.50B | 20.61B | 21.62B | 20.70B | 20.11B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 11.70B | 10.50B | 8.81B | 10.97B | 10.85B | 9.92B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -1.23B | -9.11B | -1B | -4.22B | -1.57B | -7.27B |
| Pre Tax Income | 9.79B | 690M | 6.85B | 5.81B | 8.27B | 1.66B |
| Income Tax | 1.28B | 211M | 1.24B | 1.24B | 2.07B | 1.58B |
| Net Income | 8.51B | 480M | 5.61B | 4.56B | 6.20B | 89M |
| EPS Basic | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 | 0.1 |
| EPS Diluted | 6.78 | 0.38 | 4.5 | 3.64 | 4.93 | 0.1 |
| Basic Shares Outstanding | 1.24B | 1.24B | 1.24B | 1.25B | 1.25B | 1.25B |
| Diluted Shares Outstanding | 1.24B | 1.24B | 1.24B | 1.25B | 1.25B | 1.25B |
| Ebit | 10.82B | 1.66B | 7.80B | 6.74B | 9.27B | 2.65B |
| Ebitda | 14.80B | 13.55B | 11.70B | 12.49B | 12.26B | 9.98B |
| Net Income Continuous Operations | 8.51B | 480M | 5.61B | 4.56B | 6.20B | 89M |
| Minority Interests | 0 | 0 | 52M | 26M | 24M | 34M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
